October 2014
|
A healthy pig. CC photo by thornypup on Flickr. |
When new antiviral drugs came on the
markets, many governments thought it prudent to stock-pile them in
case of any major new viral epidemic.
Accordingly, the UK government forked
out £500 million and the US government $1.3 billion largely on the
Roche version of antiviral sold as 'Tamiflu'.
The Cochrane Foundation, a global
not-for-profit organisation whose aim is “to produce accessible
health information free from commercial sponsorship and other
commercial interest”, conducted their own review of 46
pharmaceutical company-sponsored Randomised Control Trials* on the
effectiveness of Tamiflu. Such Trials are carried out routinely as
part of the drug's licensing procedure. Its conclusion was that the
benefits of this class of drug had been exaggerated. In short, the
money paid to pharmaceutical companies for such flu-treatments had
been largely wasted and could have been much better spent on other
health measures.
*Randomised
Control Trials are considered the gold standard for assessing drug
efficacy. They involve a random selection of subjects half of whom
are given the test drug and half of whom are given a placebo.
Neither the subjects nor the researchers know who has been given what
until the data on the drug's effects have been collected.
Roche, governments, health-workers and
scientists swiftly responded that Tamiflu is effective in alleviating
symptoms and saving lives.
A counter-review was then produced by
Roche: this wasn't based on scientific investigation, but on
observational evidence from 78 studies of patients admitted to
hospital. The Company claims that these “real-world” data are
more relevant to judging the efficacy of a drug than Randomised
Control Trials.
So, what happens if
you apply Roche's emphasis on real-world data to GM?